Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 10/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 9/20 | 0.42 |
| ▸ | EGFR | P00533 | 3/20 | 0.41 |
| ▸ | EIF4E | P06730 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.40 |
| ▸ | PDE4A | P27815 | 3/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.40 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13434909 | 0.92 | MKNK1 (0.42) | MKNK2MKNK1EGFREIF4EPDE4D | |
| SCHEMBL13434865 | 0.89 | MKNK2 (0.44) | MKNK2MKNK1EIF4EPDE4DPDE4A | |
| SCHEMBL3795402 | 0.87 | MKNK2 (0.48) | MKNK2MKNK1EGFREIF4EPDE4D | |
| SCHEMBL13434859 | 0.86 | MKNK2 (0.54) | MKNK2MKNK1EIF4E | |
| SCHEMBL13434887 | 0.85 | MKNK2 (0.45) | MKNK2MKNK1EGFREIF4E | |
| SCHEMBL3491815 | 0.84 | EGFR (0.46) | MKNK2MKNK1EGFREIF4E | |
| SCHEMBL13434855 | 0.84 | MKNK2 (0.48) | MKNK2MKNK1EGFR | |
| SCHEMBL3794752 | 0.81 | MEN1 (0.47) | MKNK2MKNK1EGFRPDE4DPDE4A | |
| SCHEMBL13402703 | 0.81 | MKNK2 (0.49) | MKNK2MKNK1EGFREIF4EPDE4D | |
| SCHEMBL3794206 | 0.81 | MKNK2 (0.56) | MKNK2MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633201-B2 | Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-21 | — | — | US | disclosed |
| US-8633201-B2 | Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-21 | — | — | US | disclosed |
| EP-2004656-B1 | THIENOPYRIMIDINES HAVING MNK1 /MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2013-07-10 | — | — | EP | disclosed |
| US-20100056548-A1 | THIENOPYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2010-03-04 | — | — | US | disclosed |
| US-20100056548-A1 | THIENOPYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2010-03-04 | — | — | US | disclosed |
| WO-2007115822-A1 | THIENOPYRIMIDINES HAVING MNKL /MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056548-A1 | THIENOPYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | CMPK1, DTYMK, NEK9 | MKNK2 8/4885MKNK1 29/4885EGFR 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.